Travere Therapeutics, Inc. reports developments in rare-disease biopharmaceuticals, with recurring updates on FILSPARI (sparsentan), FDA regulatory actions, commercialization in IgA nephropathy and focal segmental glomerulosclerosis, and financial results. The company focuses on therapies for rare kidney, liver, and metabolic diseases, including sparsentan and the investigational enzyme replacement therapy pegtibatinase.
Company news also covers clinical data presentations, partner-related regulatory and commercial milestones for sparsentan, capital-structure activity, inducement equity grants under Nasdaq rules, and investor-conference participation.
Travere Therapeutics (NASDAQ: TVTX) expects net product sales of approximately $51 million for Q4 2020 and $199 million for the fiscal year. The company aims to deliver first-in-class treatments for rare kidney diseases. Pivotal studies for sparsentan are on track for interim results in 2021, potentially supporting regulatory submissions. The DUPLEX study results are anticipated in February, followed by the PROTECT study in Q3. Travere expects to announce complete financial results for 2020 in late February.
Travere Therapeutics will host a virtual R&D Day on December 9, 2020, at 12:00 p.m. ET, to discuss key pipeline programs. The event will feature presentations from external experts and Travere’s senior management team, including Eric Dube, CEO, and Noah Rosenberg, CMO. Interested participants can access the live webcast on Travere's website in the 'Events & Presentations' section. A replay will be available for up to 60 days.
Travere is committed to developing therapies for patients with rare diseases.